RE: Optionality for funding17 Oct 2023 15:34
I'd reject any offer that doesn't value is properly.
A platform technology with the high likelihood of disrupting at £60bn chemotherapy market..
Worth A LOT more than £20 a share
Plus there is affirmers and diagnostics, TMAC to think about.
As soon as a offer is made a counter offer comes in, so I would expect a first offer to be very high in order to snatch avacta quickly before a competitor can move.
Like is known there is a 1.4trillion pound war chest big pharma are sat on and most are facing a patent cliff.
£30bn feels about right to me